1.Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome
Yoon-Jeong OH ; Dong-Yeop SHIN ; Sang Mee HWANG ; Sung-Min KIM ; Kyongok IM ; Hee Sue PARK ; Jung-Ah KIM ; Yeong Wook SONG ; Ana MÁRQUEZ ; Javier MARTÍN ; Dong-Soon LEE ; Jin Kyun PARK
The Korean Journal of Internal Medicine 2020;35(2):457-464
Background/Aims:
Myelodysplastic syndrome (MDS) is caused by genetic and epigenetic alteration of hematopoietic precursors and immune dysregulation. Approximately 20% of patients with MDS develop an autoimmune disease (AID). Here, we investigated whether particular genetic mutations are associated with AID in patients with MDS.
Methods:
Eighty-eight genetic mutations associated with myeloid malignancy were sequenced in 73 MDS patients. The association between these mutations and AID was then analyzed.
Results:
The median age of the 73 MDS patients was 70 years (interquartile range, 56 to 75), and 49 (67.1%) were male. AID was observed in 16 of 73 patients (21.9%). Mutations were detected in 57 (78.1%) patients. The percentage (68.8% vs. 80.7%, p = 0.32) and the mean number of mutations (1.8 ± 1.6 vs. 2.2 ± 1.8, p = 0.34) in MDS patients with or without AID were similar. However, the ten-eleven translocation- 2 (TET2) mutation rate was significantly higher in patients with AID than in those without (31.3% vs. 5.3%, respectively; p = 0.001). All TET2 mutations were variants of strong clinical significance.
Conclusions
Mutation of TET2 in patients with MDS may be associated with increased risk of developing AID.
2.Relationships between ¹⁸F-THK5351 Retention and Language Functions in Primary Progressive Aphasia
Hye Jin JEONG ; Cindy W YOON ; Seongho SEO ; Sang Yoon LEE ; Mee Kyung SUH ; Ha Eun SEO ; Woo Ram KIM ; Hyon LEE ; Jae Hyeok HEO ; Yeong Bae LEE ; Kee Hyung PARK ; Seong Hye CHOI ; Tatsuo IDO ; Kyoung Min LEE ; Young NOH
Journal of Clinical Neurology 2019;15(4):527-536
BACKGROUND AND PURPOSE: There are three distinct subtypes of primary progressive aphasia (PPA): the nonfluent/agrammatic variant (nfvPPA), the semantic variant (svPPA), and the logopenic variant (lvPPA). We sought to characterize the pattern of [¹⁸F]-THK5351 retention across all three subtypes and determine the topography of [¹⁸F]-THK5351 retention correlated with each neurolinguistic score. METHODS: We enrolled 50 participants, comprising 13 PPA patients (3 nfvPPA, 5 svPPA, and 5 lvPPA) and 37 subjects with normal cognition (NC) who underwent 3.0-tesla magnetic resonance imaging, [¹⁸F]-THK5351 positron-emission tomography scans, and detailed neuropsychological tests. The PPA patients additionally participated in extensive neurolinguistic tests. Voxel-wise and region-of-interest-based analyses were performed to analyze [¹⁸F]-THK5351 retention. RESULTS: The nfvPPA patients exhibited higher [¹⁸F]-THK5351 retention in the the left inferior frontal and precentral gyri. In svPPA patients, [¹⁸F]-THK5351 retention was elevated in the anteroinferior and lateral temporal cortices compared to the NC group (left>right). The lvPPA patients exhibited predominant [¹⁸F]-THK5351 retention in the inferior parietal, lateral temporal, and dorsolateral prefrontal cortices, and the precuneus (left>right). [¹⁸F]-THK5351 retention in the left inferior frontal area was associated with lower fluency scores. Comprehension was correlated with [¹⁸F]-THK5351 retention in the left temporal cortices. Repetition was associated with [¹⁸F]-THK5351 retention in the left inferior parietal and posterior temporal areas, while naming difficulty was correlated with retention in the left fusiform and temporal cortices. CONCLUSIONS: The pattern of [¹⁸F]-THK5351 retention was well matched with clinical and radiological findings for each PPA subtype, in agreement with the anatomical and functional location of each language domain.
Aphasia, Primary Progressive
;
Cognition
;
Comprehension
;
Humans
;
Magnetic Resonance Imaging
;
Neurofibrillary Tangles
;
Neuropsychological Tests
;
Parietal Lobe
;
Positron-Emission Tomography
;
Prefrontal Cortex
;
Rabeprazole
;
Semantics
;
Temporal Lobe
3.¹⁸F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia.
Cindy W YOON ; Hye Jin JEONG ; Seongho SEO ; Sang Yoon LEE ; Mee Kyung SUH ; Jae Hyeok HEO ; Yeong Bae LEE ; Kee Hyung PARK ; Nobuyuki OKAMURA ; Kyoung Min LEE ; Young NOH
Dementia and Neurocognitive Disorders 2018;17(3):110-119
BACKGROUND AND PURPOSE: To analyze 18F-THK5351 positron emission tomography (PET) scans of patients with clinically diagnosed nonfluent/agrammatic variant primary progressive aphasia (navPPA). METHODS: Thirty-one participants, including those with Alzheimer's disease (AD, n=13), navPPA (n=3), and those with normal control (NC, n=15) who completed 3 Tesla magnetic resonance imaging, 18F-THK5351 PET scans, and detailed neuropsychological tests, were included. Voxel-based and region of interest (ROI)-based analyses were performed to evaluate retention of 18F-THK5351 in navPPA patients. RESULTS: In ROI-based analysis, patients with navPPA had higher levels of THK retention in the Broca's area, bilateral inferior frontal lobes, bilateral precentral gyri, and bilateral basal ganglia. Patients with navPPA showed higher levels of THK retention in bilateral frontal lobes (mainly left side) compared than NC in voxel-wise analysis. CONCLUSIONS: In our study, THK retention in navPPA patients was mainly distributed at the frontal region which was well correlated with functional-radiological distribution of navPPA. Our results suggest that tau PET imaging could be a supportive tool for diagnosis of navPPA in combination with a clinical history.
Alzheimer Disease
;
Aphasia, Primary Progressive*
;
Basal Ganglia
;
Broca Area
;
Diagnosis
;
Frontal Lobe
;
Humans
;
Magnetic Resonance Imaging
;
Neurofibrillary Tangles
;
Neuropsychological Tests
;
Positron-Emission Tomography
;
Primary Progressive Nonfluent Aphasia
;
tau Proteins
4.Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial.
Youjin KIM ; Kyoung Mee KIM ; Min Gew CHOI ; Jun Ho LEE ; Tae Sung SOHN ; Jae Moon BAE ; Sung KIM ; Su Jin LEE ; Seung Tae KIM ; Jeeyun LEE ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG ; Se Hoon PARK
Journal of Gastric Cancer 2018;18(4):348-355
PURPOSE: We aimed to discuss the roles of radiation and chemotherapy as adjuvant treatment in patients with staged IB GC who were enrolled in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. MATERIALS AND METHODS: Among the 458 patients who were enrolled in the ARTIST trial, 99 had stage IB disease. The patients were randomly assigned to receive either adjuvant chemoradiotherapy with capecitabine plus cisplatin (XP, n=50) or chemoradiotherapy (XPRT, n=49). Survival analyses were performed in accordance with the AJCC 2010 staging system. RESULTS: According to the AJCC 2010 system, stage migration from IB to II occurred in 71% of the patients; 98% of the T2 N0 cases were reclassified as T3 N0, and 42% of the T1 N1 cases were reclassified as T1 N2. When comparing survival outcomes between the XPRT and XP arms for stage IB cancer (AJCC 2002), no significant difference in 5-year disease-free survival (DFS) between the 2 arms was found. (median 5-year DFS, not reached, P=0.256). The patients classified as having stage IB cancer (AJCC 2002) and reclassified as having stage II cancer (AJCC 2010) exhibited worse prognoses than those who remained in stage IB, although the difference was not statistically significant (5-year DFS rate, 83% vs. 93%). When we compared 5-year DFS in 70 patients with stage II (AJCC 2010), the addition of radiotherapy to XP chemotherapy did not show better outcome than XP alone (P=0.137). CONCLUSIONS: The role of adjuvant chemoradiotherapy in the treatment of stage IB GC (AJCC 2002) warrants further investigation.
Arm
;
Capecitabine
;
Chemoradiotherapy
;
Chemoradiotherapy, Adjuvant*
;
Chemotherapy, Adjuvant*
;
Cisplatin
;
Disease-Free Survival
;
Drug Therapy
;
Humans
;
Prognosis
;
Radiotherapy*
;
Stomach Neoplasms*
;
Stomach*
5.Altered Cortical Thicknesses of Left Pars Opercularis and Left Lateral Occipital Gyrus Can Be Associated with Psychotic Symptoms in Patients with Alzheimer's Disease.
Doo Hyoung LEE ; Gyung Mee KIM ; Seon Cheol PARK ; Tae Hyung KIM ; Seung Eun CHOI ; Tae Yeong JEONG ; Bong Ju LEE ; Chi Woong MUN ; Jung Goo LEE ; Young Hoon KIM
Journal of Korean Geriatric Psychiatry 2017;21(2):67-74
OBJECTIVE: The aims of this study was to present an association between the presence of psychotic symptoms and cortical thicknesses/subcortical volumes in patients with Alzheimer's disease (AD). METHODS: Fourteen AD patients with psychotic symptoms and 41 without psychotic symptoms underwent 3T MRI scanning. After adjusting the effects of confounding variables, the cortical thicknesses were compared between the AD patients with and without psychotic symptoms in multiple regions, across the continuous cortical surface. In addition, the subcortical volumes were compared with a structure-by-structure manner. RESULTS: AD patients with psychotic symptoms were characterized by significant smaller cortical thickness of left pars opercularis (F=4.67, p=0.02) and left lateral occipital gyrus (F=6.05, p=0.04) rather than those without psychotic symptoms, after adjusting the effects of age and scores on the Stroop test, non-psychotic items of Neuropsychiatry Inventory and Clinical Dementia Rating, triglyceride level and total intracranial volume. However, there were no significant differences in the subcortical volume between the two groups. CONCLUSION: These results suggest that AD psychosis may reflect more severe deterioration of neuropathologic change in specific brain region.
Alzheimer Disease*
;
Brain
;
Broca Area*
;
Confounding Factors (Epidemiology)
;
Dementia
;
Humans
;
Magnetic Resonance Imaging
;
Neuropsychiatry
;
Occipital Lobe*
;
Psychotic Disorders
;
Stroop Test
;
Triglycerides
6.The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial.
Youjin KIM ; Se Hoon PARK ; Kyoung Mee KIM ; Min Gew CHOI ; Jun Ho LEE ; Tae Sung SOHN ; Jae Moon BAE ; Sung KIM ; Su Jin LEE ; Seung Tae KIM ; Jeeyun LEE ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG
Journal of Gastric Cancer 2016;16(2):105-110
PURPOSE: In the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial, we investigated whether chemoradiotherapy after D2 gastrectomy reduces the rate of recurrence. Recently, the ratio of metastatic lymph nodes to examined lymph nodes (N ratio) has been proposed as an independent prognostic factor in gastric cancer (GC). The aim of this study was to investigate the relationship between the metastatic N ratio and prognosis of GC after curative D2 surgery. MATERIALS AND METHODS: We retrospectively reviewed the data of 458 ARTIST patients who underwent D2 gastrectomy followed by adjuvant chemotherapy (XP, n=228) or chemoradiotherapy (XPRT, n=230). The disease-free survival (DFS) rates of patients were used to evaluate the influence of N ratio on the treatment outcome. To achieve this, 4 different N ratio categories (0%, 1%~9%, 10%~25%, and >25%) were compared on the basis of their influence on the treatment outcome. RESULTS: On multivariate analysis, the N ratio remained an independent prognostic factor for DFS. The hazard ratios (HRs) for the N ratio categories of 0%, 1%~9%, 10%~25%, and >25% were 1, 1.061, 1.202, and 3.571, respectively. In patients having N ratio >25%, the 5-year DFS rates were 55% and 28% for the XPRT and XP arms, respectively (HR, 0.527; 95% confidence interval, 0.307~0.904; P=0.020). CONCLUSIONS: In patients with curatively resected GC, the N ratio was independently associated with DFS. Although this finding warrants further investigation in future prospective studies, the benefit of chemoradiotherapy for D2 resected GC appears to be more beneficial in cancers having N ratios >25%.
Arm
;
Chemoradiotherapy
;
Chemoradiotherapy, Adjuvant*
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Gastrectomy
;
Humans
;
Lymph Nodes*
;
Multivariate Analysis
;
Prognosis
;
Prospective Studies
;
Recurrence
;
Retrospective Studies
;
Stomach Neoplasms
;
Stomach*
;
Treatment Outcome
7.Effect of Peritoneal Dialysis Modality on the 1-Year Rate of Decline of Residual Renal Function.
Chan Ho KIM ; Hyung Jung OH ; Mi Jung LEE ; Young Eun KWON ; Yung Ly KIM ; Ki Heon NAM ; Kyoung Sook PARK ; Seong Yeong AN ; Kwang Il KO ; Hyang Mo KOO ; Fa Mee DOH ; Seung Hyeok HAN ; Tae Hyun YOO ; Beom Seok KIM ; Shin Wook KANG ; Kyu Hun CHOI
Yonsei Medical Journal 2014;55(1):141-148
PURPOSE: The effect of different peritoneal dialysis (PD) modalities on the decline in residual renal function (RRF) is unclear due to inconsistencies among studies. In particular, the effect of automated peritoneal dialysis (APD) modalities [continuous cyclic peritoneal dialysis (CCPD) and nightly intermittent peritoneal dialysis (NIPD)] on RRF has not been examined in a large cohort. MATERIALS AND METHODS: We conducted a single-center retrospective study to investigate the association between PD modalities and decline in RRF in 142 incident PD patients [34 on CCPD, 36 on NIPD, and 72 on continuous ambulatory peritoneal dialysis (CAPD)]. RRF was measured within 2 months from PD start and at 1 year after PD initiation. RESULTS: The RRF at 1 year after PD initiation was 1.98+/-2.20 mL/min/1.73 m2 in CCPD patients and 3.63+/-3.67 mL/min/1.73 m2 in NIPD patients, which were moderately lower than 4.23+/-3.51 mL/min/1.73 m2 in CAPD patients (p=0.064). Moreover, there was no significant difference in the 1-year rate of decline of RRF between CCPD and NIPD patients, although APD patients had a faster 1-year RRF decline rate than CAPD patients (CCPD and NIPD vs. CAPD: -45.68 and -36.69 vs. 1.17%/year, p=0.045). APD was associated with a more rapid decline in RRF in patients with end-stage renal disease undergoing PD, although multivariate analysis attenuated the significance of this finding (beta=-31.50; 95% CI, -63.61 to 0.62; p=0.052). CONCLUSION: Our results suggest that CAPD might be more helpful than APD for preserving RRF during the first year of dialysis therapy, although there was no significant difference in the 1-year rate of decline of RRF between the two APD modalities.
Adult
;
Female
;
Glomerular Filtration Rate/physiology
;
Humans
;
Kidney/pathology/physiopathology
;
Kidney Failure, Chronic/*therapy
;
Male
;
Middle Aged
;
Peritoneal Dialysis/*adverse effects
;
Retrospective Studies
8.Paracentric Inversions Found in Prenatal Diagnosis.
Shin Yeong LEE ; Bom Yi LEE ; Ju Yeon PARK ; Eun Young CHOI ; Yeon Woo LEE ; Ah Rum OH ; Hyun Mee RYU ; So Yeon PARK
Journal of Genetic Medicine 2013;10(2):104-108
PURPOSE: This study was designed to confirm whether the paracentric inversions of fetuses and parents may be harmless. MATERIALS AND METHODS: We report 10 cases (0.14%) with paracentric inversions among 7,181 prenatal cases observed during prenatal diagnosis performed at Cheil General Hospital between January 2009 and June 2013. We used cytogenetic GTL- and RBG-banding techniques. RESULTS: Of the 10 cases, nine cases were transmitted from each of the parents, and one case was de novo. Nine cases were phenotypically normal up to one month of age after birth. One case was lost to follow-up. We present prenatal diagnosis and follow-up examination of the fetuses with paracentric inversion. CONCLUSION: Based on our cases, most paracentric inversions are considered to be harmless. The precise identification of paracentric inversions might be clinically important and helpful for genetic counseling.
Amniocentesis
;
Chorionic Villi Sampling
;
Cytogenetics
;
Female
;
Fetus
;
Follow-Up Studies
;
Genetic Counseling
;
Hospitals, General
;
Humans
;
Lost to Follow-Up
;
Parents
;
Parturition
;
Pregnancy
;
Prenatal Diagnosis*
9.Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy.
Jina YUN ; Kyoung Mee KIM ; Seung Tae KIM ; Jung Hoon KIM ; Jung A KIM ; Jee Hyun KONG ; Soo Hyeon LEE ; Young Woong WON ; Jong Mu SUN ; Jeeyun LEE ; Se Hoon PARK ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG
Cancer Research and Treatment 2010;42(2):101-106
PURPOSE: The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy. MATERIALS AND METHODS: A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei. RESULTS: Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%). CONCLUSION: In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.
Cell Nucleus
;
Cisplatin
;
Deoxycytidine
;
Epirubicin
;
Fluorouracil
;
Humans
;
Stomach Neoplasms
;
Survival Rate
;
Capecitabine
10.Practical Standardization in Renal Biopsy Reporting.
So Young JIN ; Hyeon Joo JEONG ; Sun Hee SUNG ; Beom Jin LIM ; Jee Young HAN ; Soon Won HONG ; Hyun Ee YIM ; Yeong Jin CHOI ; Yong Mee CHO ; Myoung Jae KANG ; Kyung Chul MOON ; Hee Jeong CHA ; Seung Yeon HA ; Mi Seon KANG ; Mee Young SO ; Kwang Sun SUH ; Jong Eun JOO ; Yong Jin KIM ; Nam Hee WON ; Moon Hyang PARK
Korean Journal of Pathology 2010;44(6):613-622
BACKGROUND: To standardize renal biopsy reporting and diagnosis, The Renal Pathology Study Group of the Korean Society of Pathologists (RPSKSP) has developed a renal pathology reporting format for the native and allograft kidney. METHODS: A consensus checklist of a provisional renal biopsy format was sent to all members of the RPSKSP. Feed back opinions regarding the practical application of the checklist to the diagnostic work were received. RESULTS: Kidney biopsies require three essential examinations: by light microscopy, immunofluorescence (IF), and electron microscopy (EM). A final report of a renal biopsy should include information on specimen adequacy and a description of the morphologic change using a systematic semiquantitative method for each of the compartments, with optional separate IF and EM reports. CONCLUSIONS: A standard renal biopsy report format is important in establishing clinicopathologic correlations, making reliable prognostic considerations, comparing the findings in sequential biopsies and evaluating the effects of therapy.
Biopsy
;
Checklist
;
Consensus
;
Kidney
;
Light
;
Microscopy, Electron
;
Microscopy, Fluorescence
;
Transplantation, Homologous

Result Analysis
Print
Save
E-mail